Abstract 3277: SWI/SNF inactivation vulnerability
Authors: Andrea Vilarrubi, Fernando Setien, Eva Pros, Pedro P. Medina, Antonio Gomez, Alberto Villanueva, Octavio A. Romero, Montse Sanchez-Cespedes
Journal: Cancer Research (2022)

Abstract Genetic inactivation in specific SWI/SNF complex members induce sensitivity to the inhibition of KDM6A/UTX and KDM6B/JMJD3 in cancer. Despite the genetic inactivation of the tumor suppressor SMARCA4 is frequently found in cancer, there are no therapies that effectively target SMARCA4-deficient tumors. In our previous work, we reported that unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. In this context, SMARCA4 deficient cells showed an impaired transactivation and significantly reduced levels of the histone H3K27me3 specific demethylases, KDM6A/UTX and KDM6B/JMJD3, and their inhibition compromises cell viability specifically in SMARCA4 mutant cells. Furthermore, the in vivo administration of KDM6s inhibitor (GSK-J4) to mice orthotopically implanted with SMARCA4 mutant lung cancer cell lines or primary tumors of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), showed a strong anti-tumor effect, highlighting the vulnerability of the SMARCA4 deficient tumors to KDM6s inhibition as a biomarker that could be exploited for treating SMARCA4-mutant cancer patients (Romero OA, Vilarrubi A, et al. SMARCA4 deficient tumors are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Comm 12, 4319, 2021). Considering our previous observations, and due to the biological role of SMARCA4 as a core component of the SWI/SNF chromatin-remodeling complex, whose members are genetically inactivated in approximately 20% of all human cancers, we wanted to determine the potential response to KDM6s inhibitors in a context of genetic alterations in genes encoding for the other subunits of this remodeling complex. For this propose, we have integrated state of the art technology like genome-wide chromatin modification analysis (ChIP-seq) and transcriptome analysis (RNA-seq), using human cancer cell lines and preclinical models of different cancer types with genetic inactivation at different SWI/SNF-complex members, including mouse models such as orthoxenografts, to design a personalized epigenetic treatment based on the genetic background. Our results showed that, like SMARCA4 deficient cells, specific mutations at some, but not all, SWI/SNF components induce refractoriness to SAHA, aberrant increase of H3K27me3 mark and sensitizes cancer cells to KDM6 inhibitor accompanied with significantly reduced levels of KDM6A and KDM6B expression. These results suggest a strong functional relationship between KDM6A/6B activity and the SWI/SNF-complex, in the control of gene expression and cancer development. These results will be of great value for the stratification of tumors according to their genetic background for tailored treatments, opening the possibility to use SWI/SNF mutations as potential biomarkers for personalized epigenetic-based therapeutics in cancer. Citation Format: Andrea Vilarrubi, Fernando Setien, Eva Pros, Pedro P. Medina, Antonio Gomez, Alberto Villanueva, Octavio A. Romero, Montse Sanchez-Cespedes. SWI/SNF inactivation vulnerability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3277.